Alzheimer's disease (AD) is a neurodegenerative disorder with a high negative impact in terms of cost and social issues. New kinds of noninvasive, reliable, easy-to-use, and cheap biosensors are highly...
Angiogenin is a potent angiogenic factor overexpressed in many cancers. In this study, we report the characterization of copper(II) complexes of two peptides from the 40–50 angiogenin domain by means...
Phosphomannomutase-2 (PMM2) deficiency represents the most common congenital disorder of glycosylation (CDG). Currently, little is known about cell metabolic alterations occurring in these patients. Here, we quantified compounds connected to...
Peptide nucleic acids (PNAs) have garnered significant attention due to their enhanced chemical, physical, and binding properties in comparison to natural nucleic acids. This prompted their application in antigene/antisense approach,...
Mucin 1 (MUC1) is a promising antigen for cancer vaccine development, but its low immunogenicity poses a major challenge. In this study, we have investigated the effect of varying the...
Coumarin represents a privileged structural motif that is quite common in nature-derived and synthetic bioactive molecules. Some of us have recently described the straightforward preparation of complex furo[3,2-c]coumarins through a...
Peptide's applications frequently present problems of solubility, stability, activity, or membrane permeability. To overcome these issues, cyclodextrins (CDs) can be used to form inclusion complexes with peptide hydrophobic parts; alkyl-chains...
Whey protein concentrate (WPC)/omega-3 rich oil/TiO2 nanocomposite films were prepared by casting as a bio-based alternative to petroleum-based plastics. The effect of adding Tween 20 and/or TiO2 nanoreinforcement in two...
: Chimera-type galectin-3 (Gal-3) is a β-galactoside-binding protein containing a single conserved carbohydrate-recognition domain, crucial in fibrosis and carcinogenesis. Selenium-based Gal-3 inhibitors have emerged as promising therapeutic agents, particularly for...
